CSF2 and cancer: The recent approval of talimogene laherparepvec (T-VEC, Imlygic), a herpes simplex virus (HSV) armed with granulocyte macrophage colony stimulating factor (GM-CSF), has paved the way in acknowledging OVT as a valid therapeutic option with a key role to play in the new era of cancer immunotherapies (11).